Arrowhead Pharmaceuticals Inc. is a Arrowhead Pharmaceuticals Inc is an American biotechnology company.
Arrowhead Pharmaceuticals Inc. (ARWR) had a good day on the market for Wednesday December 02 as shares jumped 3.32% to close at $64.72. About 856,243 shares traded hands on 10,079 trades for the day, compared with an average daily volume of n/a shares out of a total float of 102.76 million. After opening the trading day at $62.03, shares of Arrowhead Pharmaceuticals Inc. stayed within a range of $65.00 to $61.21.
With today’s gains, Arrowhead Pharmaceuticals Inc. now has a market cap of $6.65 billion. Shares of Arrowhead Pharmaceuticals Inc. have been trading within a range of $0.00 and $0.00 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Arrowhead Pharmaceuticals Inc. is based out of Pasadena, CA and has some 109 employees. Its CEO is Christopher Anzalone.